Podcast: FDA's Califf Talks About Combo Product Reform, Commish Prospects
This article was originally published in The Gray Sheet
Executive Summary
In an exclusive interview with "The Gray Sheet," FDA's Deputy Commissioner Robert Califf spoke about concerns the agency has with regulating combination products, provides tips for companies looking to get combo products to market and whether he'd consider taking on the role of FDA commissioner. Listen to our exclusive podcast or read the Q&A transcript.
You may also be interested in...
Commissioner Califf: Cardiologist, Clinical Trials Expert Ascends At FDA
The Senate confirmed Robert Califf as the new FDA commissioner after months of delay, giving the cardiologist, clinical trial expert and established agency official a better platform to push his priorities, which include combination product and clinical data-collection reforms, while implementing projects already under way.
2016 Will Be A Big Year For Combo Product Reform, FDA Says
Having earlier signaled its plan to propose a new statutory pathway for combination products by the end of 2016, the agency is now working on a bevy of process changes, guidance documents and rules to enhance premarket and postmarket regulation of combination products in the years ahead.
2016 Will Be A Big Year For Combo Product Reform, FDA Says
The agency has already signaled its plan to propose a new statutory pathway for combination products by the end of next year. In the meantime, it's working on a bevy of process changes, guidance documents and rules to enhance premarket and postmarket regulation of combination products in the years ahead. Office of Combination Products officials John Weiner and Thinh Nguyen weigh in.